Perception of prescription drug monitoring programs as a prevention tool in primary medical care

Amie J. Goodin; Joshua D. Brown; Chris Delcher; Patricia R. Freeman; Jeffery Talbert; Stephen G. Henry; Dikea Roussos-Ross

doi:10.1016/j.sapharm.2019.03.012

Perception of prescription drug monitoring programs as a prevention tool in primary medical care

Amie J. Goodin, Joshua D. Brown, Chris Delcher, Patricia R. Freeman, Jeffery Talbert, Stephen G. Henry, Dikea Roussos-Ross

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background: Prescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable. Objective: To examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs). Methods: Independent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests. Results: In Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1% OB/GYN vs. 83.7% PCP “agree positive impact”; Kentucky: 45.0% OB/GYN vs. 68.5% PCP “effective”. California: 73.2% OB/GYN vs. 86.4% PCP “useful”. Conclusions: These results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.

Original language	English
Pages (from-to)	1306-1308
Number of pages	3
Journal	Research in Social and Administrative Pharmacy
Volume	16
Issue number	9
DOIs	https://doi.org/10.1016/j.sapharm.2019.03.012
State	Published - Sep 2020

Bibliographical note

Funding Information:
This project was not funded directly, but secondary analysis was conducted using survey data acquired with permission from: the University of Kentucky Institute for Pharmaceutical Outcomes and Policy, House Bill 1 Impact Evaluation of Kentucky's Prescription Drug Monitoring Program (Harold Rogers Grant #: 2011-PM-BX-2007, awarded by Bureau of Justice Assistance); the University of Florida (Harold Rogers Grant #: 2013-PM-BX-0010, awarded by Bureau of Justice Assistance); The California Department of Justice (Harold Rogers Grant #2015-PM-BX-K001, awarded by Bureau of Justice Assistance), and the California Department of Public Health (Prevention for States grant #1U17CE002747, awarded by the CDC).

Funding Information:
The authors wish to thank and acknowledge the research teams from the University of Kentucky (SuZanne Troske), the University of Florida (Yanning Wang, Bruce A. Goldberger), and the California Department of Public Health (John Pugliese), for sharing survey data collected during their respective evaluations of each state's Prescription Drug Monitoring Program.

Publisher Copyright:
© 2019 Elsevier Inc.

Keywords

Controlled substance use in pregnancy
Neonatal abstinence syndrome
Opioid analgesics
Prescription drug monitoring programs

ASJC Scopus subject areas

Pharmacy
Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.sapharm.2019.03.012

Cite this

@article{3a52101579f44d4e8f48adb7fa9d1cf5,

title = "Perception of prescription drug monitoring programs as a prevention tool in primary medical care",

abstract = "Background: Prescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable. Objective: To examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs). Methods: Independent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests. Results: In Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1% OB/GYN vs. 83.7% PCP “agree positive impact”; Kentucky: 45.0% OB/GYN vs. 68.5% PCP “effective”. California: 73.2% OB/GYN vs. 86.4% PCP “useful”. Conclusions: These results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.",

keywords = "Controlled substance use in pregnancy, Neonatal abstinence syndrome, Opioid analgesics, Prescription drug monitoring programs",

author = "Goodin, {Amie J.} and Brown, {Joshua D.} and Chris Delcher and Freeman, {Patricia R.} and Jeffery Talbert and Henry, {Stephen G.} and Dikea Roussos-Ross",

note = "Funding Information: This project was not funded directly, but secondary analysis was conducted using survey data acquired with permission from: the University of Kentucky Institute for Pharmaceutical Outcomes and Policy, House Bill 1 Impact Evaluation of Kentucky's Prescription Drug Monitoring Program (Harold Rogers Grant #: 2011-PM-BX-2007, awarded by Bureau of Justice Assistance); the University of Florida (Harold Rogers Grant #: 2013-PM-BX-0010, awarded by Bureau of Justice Assistance); The California Department of Justice (Harold Rogers Grant #2015-PM-BX-K001, awarded by Bureau of Justice Assistance), and the California Department of Public Health (Prevention for States grant #1U17CE002747, awarded by the CDC). Funding Information: The authors wish to thank and acknowledge the research teams from the University of Kentucky (SuZanne Troske), the University of Florida (Yanning Wang, Bruce A. Goldberger), and the California Department of Public Health (John Pugliese), for sharing survey data collected during their respective evaluations of each state's Prescription Drug Monitoring Program. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = sep,

doi = "10.1016/j.sapharm.2019.03.012",

language = "English",

volume = "16",

pages = "1306--1308",

number = "9",

}

TY - JOUR

T1 - Perception of prescription drug monitoring programs as a prevention tool in primary medical care

AU - Goodin, Amie J.

AU - Brown, Joshua D.

AU - Delcher, Chris

AU - Freeman, Patricia R.

AU - Talbert, Jeffery

AU - Henry, Stephen G.

AU - Roussos-Ross, Dikea

N1 - Funding Information: This project was not funded directly, but secondary analysis was conducted using survey data acquired with permission from: the University of Kentucky Institute for Pharmaceutical Outcomes and Policy, House Bill 1 Impact Evaluation of Kentucky's Prescription Drug Monitoring Program (Harold Rogers Grant #: 2011-PM-BX-2007, awarded by Bureau of Justice Assistance); the University of Florida (Harold Rogers Grant #: 2013-PM-BX-0010, awarded by Bureau of Justice Assistance); The California Department of Justice (Harold Rogers Grant #2015-PM-BX-K001, awarded by Bureau of Justice Assistance), and the California Department of Public Health (Prevention for States grant #1U17CE002747, awarded by the CDC). Funding Information: The authors wish to thank and acknowledge the research teams from the University of Kentucky (SuZanne Troske), the University of Florida (Yanning Wang, Bruce A. Goldberger), and the California Department of Public Health (John Pugliese), for sharing survey data collected during their respective evaluations of each state's Prescription Drug Monitoring Program. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2020/9

Y1 - 2020/9

N2 - Background: Prescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable. Objective: To examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs). Methods: Independent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests. Results: In Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1% OB/GYN vs. 83.7% PCP “agree positive impact”; Kentucky: 45.0% OB/GYN vs. 68.5% PCP “effective”. California: 73.2% OB/GYN vs. 86.4% PCP “useful”. Conclusions: These results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.

AB - Background: Prescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable. Objective: To examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs). Methods: Independent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests. Results: In Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1% OB/GYN vs. 83.7% PCP “agree positive impact”; Kentucky: 45.0% OB/GYN vs. 68.5% PCP “effective”. California: 73.2% OB/GYN vs. 86.4% PCP “useful”. Conclusions: These results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.

KW - Controlled substance use in pregnancy

KW - Neonatal abstinence syndrome

KW - Opioid analgesics

KW - Prescription drug monitoring programs

UR - http://www.scopus.com/inward/record.url?scp=85063446987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063446987&partnerID=8YFLogxK

U2 - 10.1016/j.sapharm.2019.03.012

DO - 10.1016/j.sapharm.2019.03.012

M3 - Article

C2 - 30935769

AN - SCOPUS:85063446987

VL - 16

SP - 1306

EP - 1308

IS - 9

ER -

Perception of prescription drug monitoring programs as a prevention tool in primary medical care

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this